{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:01:25Z","timestamp":1790755285473,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,30]],"date-time":"2027-09-30T00:00:00Z","timestamp":1822262400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY022589"],"award-info":[{"award-number":["P30EY022589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP5OD029610"],"award-info":[{"award-number":["DP5OD029610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY034146"],"award-info":[{"award-number":["R01EY034146"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32EY026590"],"award-info":[{"award-number":["T32EY026590"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["OT2OD032644"],"award-info":[{"award-number":["OT2OD032644"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.oret.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:37:03Z","timestamp":1780357023000},"page":"1017-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-1915","authenticated-orcid":false,"given":"Shahin","family":"Hallaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8312-6623","authenticated-orcid":false,"given":"Takashi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2916-9187","authenticated-orcid":false,"given":"Alireza","family":"Kamalipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4908-6856","authenticated-orcid":false,"given":"Christopher A.","family":"Longhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-2500","authenticated-orcid":false,"given":"William R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-7690","authenticated-orcid":false,"given":"Sally L.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Boussina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.05.016_bib1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","article-title":"Age-related macular degeneration","volume":"401","author":"Guymer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.05.016_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2026.05.016_bib3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2026.05.016_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","article-title":"The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD","volume":"60","author":"Datta","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2026.05.016_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.oret.2026.05.016_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bph.15683","article-title":"The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma","volume":"179","author":"Cui","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.oret.2026.05.016_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","article-title":"Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration","volume":"143","author":"Shor","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.05.016_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.05.016_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.oret.2025.12.016","article-title":"Rate of age-related macular degeneration in patients prescribed glucagon-like peptide-1 receptor agonists or other weight loss therapies","volume":"10","author":"Myers","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.05.016_bib10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.oret.2025.12.014","article-title":"Impact of glucagon-like peptide-1 receptor agonists on age-related macular degeneration at a tertiary ophthalmology center","volume":"10","author":"Joo","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.05.016_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.oret.2025.10.020","article-title":"Glucagon-like peptide-1 receptor agonist use and risk of neovascular age-related macular degeneration in a National Cohort Study","volume":"10","author":"Allan","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.05.016_bib12","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/IAE.0000000000004616","article-title":"Impact of GLP-1 receptor agonists for type 2 diabetes mellitus on the development and progression of age-related macular degeneration","volume":"45","author":"McLaughlin","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.05.016_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaophthalmol.2025.3821","article-title":"Glucagon-like peptide-1 receptor agonists and age-related macular degeneration","volume":"143","author":"Ahuja","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.05.016_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change","volume":"269","author":"Hallaj","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.05.016_bib15","first-page":"467","article-title":"Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM)","volume":"245","author":"You","year":"2017","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.oret.2026.05.016_bib16","unstructured":"University of California Health. Center for data-driven insights and innovation (CDI2). Accessed March 15, 2024. https:\/\/www.ucop.edu\/uc-health\/departments\/center-for-data-driven-insights-and-innovations-cdi2.html."},{"key":"10.1016\/j.oret.2026.05.016_bib17","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2025.06.014","article-title":"Association between nucleoside and nucleotide reverse transcriptase inhibitor use and primary open-angle glaucoma risk in All of Us","volume":"132","author":"Pham","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.05.016_bib18","unstructured":"Health, United States. Race. Centers for Disease Control and Prevention. Accessed September 8, 2025. https:\/\/www.cdc.gov\/nchs\/hus\/sources-definitions\/race.html."},{"key":"10.1016\/j.oret.2026.05.016_bib19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hernandez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2026.05.016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104624","article-title":"Protective effect of Liraglutide on diabetic retinal neurodegeneration via inhibiting oxidative stress and endoplasmic reticulum stress","volume":"133","author":"Liu","year":"2020","journal-title":"Neurochem Int"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026002666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026002666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:41:01Z","timestamp":1790754061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026002666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2468653026002666"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.05.016","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s40135-026-00357-w","asserted-by":"object"}]},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}